Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol
; 185(5): 948-951, 2019 06.
Article
in En
| MEDLINE
| ID: mdl-30460696
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Transplantation, Autologous
/
Bortezomib
/
Multiple Myeloma
/
Antineoplastic Agents
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Br J Haematol
Year:
2019
Type:
Article
Affiliation country:
United kingdom